The Research, Scholarship, and Artistic Achievement Awards nomination deadline has been extended to May 31, 2024. Click here for more information.

Immunoprotective Primary Mesenchymal Stem Cells


Tulane University is actively seeking commercial entities to further develop and commercialize novel immunoprotective primary mesenchymal stem cells to target pathological agents.


Mesenchymal stem cells (MSC) are unique multipotent progenitor cells that are presently being exploited as gene therapy vectors for a variety of conditions, including cancer and autoimmune diseases. While MSC are primarily touted for their immunosuppressive properties, several published reports have also directly shown that MSC promotes adaptive immunity. DNA vaccination studies in humans show poor efficacy. Dendritic cell vaccination strategies have shown limited clinical success for therapeutic cancer vaccinations and have high production costs due to necessary individual tailoring. A further limitation on current vaccine technology is the time involved in developing a vaccine against a given pathogen. Episomally transfected MSC address the limitations of vaccinations. Immunoprotective primary MSCs are useful for generating passive immunity against or treating infection by the pathological agent. It can be provided in a pharmaceutically acceptable carrier, such as a buffer, for use as a pharmaceutical composition for treatment or prevention.


Luis M. Branco, PhD
Bruce A. Bunnell, PhD
Russell B. Wilson, PhD
Samuel E. Hopkins

Available For

Exclusive License in a Field
Non-exclusive License
Scientific Collaboration

For more information, please contact: